Breast Cancer clinical trials in South Dakota

11 actively recruiting breast cancer trials at 3 sites across South Dakota.

Data from ClinicalTrials.gov · last refreshed 2026-08-10

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

QuantumLeap Healthcare Collaborative funds and runs this clinical trial (NCT01042379). In 2024, QuantumLeap Healthcare Collaborative reported paying the doctors leading the trial a total of $1,241,104 for research work on this study.

Who paid

Regeneron Pharmaceuticals, Inc. $1,241,104

Paid for research work on this trial

AMY CHIEN(oncologist on CancerDrs) $173,543
CORAL OMENE(oncologist on CancerDrs) $170,862
ANTHONY ELIAS(oncologist on CancerDrs) $129,619
ANNE WALLACE $119,648
ERICA STRINGER(oncologist on CancerDrs) $91,709

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology

NCT ID: NCT04852887

Sites in South Dakota:

Rapid City Regional Hospital — Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT06876714

Sites in South Dakota:

Rapid City Regional Hospital — Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology

NCT ID: NCT06748222

Sites in South Dakota:

Rapid City Regional Hospital — Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca

NCT ID: NCT05952557

Sites in South Dakota:

Research Site — Aberdeen, South Dakota
Research Site — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06393374

Sites in South Dakota:

Sanford Cancer Center ( Site 0059) — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564377

Sites in South Dakota:

Rapid City Regional Hospital — Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…

Sponsor: QuantumLeap Healthcare Collaborative

NCT ID: NCT01042379

Sites in South Dakota:

Sanford Clinical Research — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim

NCT ID: NCT06324357

Sites in South Dakota:

Avera Cancer Institute — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

NCT ID: NCT04389632

Sites in South Dakota:

Sanford Cancer Center — Sioux Falls, South Dakota
Sanford USD Medical Center — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at ag…

Sponsor: University of California, San Francisco

NCT ID: NCT02620852

Sites in South Dakota:

Edith Sanford Breast Center — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Recruiting Academic/Other

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patien…

Sponsor: Sanford Health

NCT ID: NCT01793168

Sites in South Dakota:

Sanford Health — Sioux Falls, South Dakota

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10